<?xml version="1.1" encoding="UTF-8" standalone="yes"?><xml><head><creation_date>D:20050607113617+02'00'</creation_date><modification_date>D:20060322173355+01'00'</modification_date><initial_authorization>False</initial_authorization><pdf_file>EU-1-04-283_h_dec_1.pdf</pdf_file></head><body><section><header>en  
   en</header></section><section><header>en</header><p>commission of the european communities</p><p>brussels, 03-vi-2005 c(2005)1734 
 not for publication</p></section><section><header>commission decision of 03-vi-2005 
 amending the marketing authorisation for &quot;ariclaim - duloxetine hydrochloride&quot;, a 
 medicinal product for human use, granted by decision c(2004)3160</header><p>only the german text is authentic</p></section><section><header>en  
   en</header></section><section><header>commission decision of 03-vi-2005 
 amending the marketing authorisation for &quot;ariclaim - duloxetine hydrochloride&quot;, a 
 medicinal product for human use, granted by decision c(2004)3160 
 (text with eea relevance)</header><p>the commission of the european communities, having regard to the treaty establishing the european community,</p><p>
 having regard to council regulation (eec) no 2309/93 of 22 july 1993 laying down 
 community procedures for the authorization and supervision of medicinal products for 
 human and veterinary use and establishing a european agency for the evaluation of 
 medicinal products
 1, having regard to commission regulation (ec) no 1085/2003 of 3 june 2003 concerning 
 the examination of variations to the terms of a marketing authorisation for medicinal 
 products for human use and veterinary medicinal products falling within the scope of 
 council regulation (eec) no 2309/93
 2, and in particular the third subparagraph of article 4(5) thereof, 
 having regard to the notifications submitted by boehringer ingelheim international 
 gmbh under article 4(1) of regulation (ec) no 1085/2003, 
 whereas: 
 (1)</p><p>the european medicines agency acknowledged, between 8 september 2004 and 
 8 march 2005, the validity of the notification(s) for minor variations of type ia, 
 informing the marketing authorisation holder accordingly, and has prepared a list 
 of the notification(s). the variation(s) took effect from the date of the 
 communication from the european medicines agency concerning the validation. 
 (2)</p><p>the marketing authorisation should be updated, and decision c(2004)3160 of 11 
 august 2004 amended accordingly. 
 (3)</p><p>for the sake of clarity and transparency, it is advisable, following the amendment 
 of part or parts of the annexes, to provide for a consolidated version thereof. the 
 annexes to decision c (2004)3160 should therefore be replaced,</p><p>
 1 oj l 214, 24.8.1993, p. 1. regulation as amended by commission regulation (ec) no 649/98 (oj l 88, 24.3.1998, p. 7). 
 2 oj l 159, 27.6.2003, p. 24.</p></section><section><header>en  
   en</header><p>has adopted this decision: article 1 decision c(2004)3160 is amended as follows: 1) the list of notifications for minor variations of type ia, the validity of which was 
 acknowledged between 8 september 2004 and 8 march 2005, is added to the updated 
 marketing authorisation; 
 application number 
 scope (eu numbers affected) 
 emea/h/c/552/ia/001 
 8.b.1 (ia) (eu/1/04/283/001-006) 
 2) annex ii is replaced by the text set out in annex ii to this decision; 
 3) annex iii b is replaced by the text set out in annex iii b to this decision. 
 article 2 this decision is addressed to boehringer ingelheim international gmbh, binger strasse 173, d-55216 ingelheim am rhein, deutschland. 
 done at brussels, 03-vi-2005 
 for the commission g√ºnter verheugen 
 member of the commission</p></section></body></xml>